(Q35603895)

9 August 2017

1 reference

title

The role of positron emission tomographic imaging in breast cancer (English)

1 reference

9 August 2017

Michelle D McDonough

1

1 reference

9 August 2017

Elizabeth R DePeri

series ordinal

2

1 reference

9 August 2017

Betty A Mincey

series ordinal

3

1 reference

9 August 2017

publication date

1 January 2004

1 reference

9 August 2017

published in

Current Oncology Reports

1 reference

9 August 2017

volume

6

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

62-68

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-996-0011-y

9 August 2017

exact match

0 references

cites work

Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants.

1 reference

https://api.crossref.org/works/10.1007%2FS11912-996-0011-Y

The positive predictive value of mammography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-996-0011-Y

The prevalence of carcinoma in palpable vs impalpable, mammographically detected lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-996-0011-Y

Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-996-0011-Y

Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-996-0011-Y

Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy

21 January 2018

1 reference

12 December 2020

Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico

1 reference

12 December 2020

The Potential of F-18-FDG PET in Breast Cancer. Detection of Primary Lesions, Axillary Lymph Node Metastases, or Distant Metastases

1 reference

12 December 2020

Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.

1 reference

12 December 2020

Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation?

1 reference

12 December 2020

Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation

1 reference

12 December 2020

Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer

1 reference

12 December 2020

Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose

1 reference

12 December 2020

Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations

1 reference

12 December 2020

Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer

1 reference

12 December 2020

Metabolic flare: indicator of hormone responsiveness in advanced breast cancer

1 reference

12 December 2020

Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers

1 reference

12 December 2020

Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose

1 reference

12 December 2020

Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective

1 reference

12 December 2020

The Place of Whole-Body PET FDG for the Diagnosis of Distant Recurrence of Breast Cancer

1 reference

12 December 2020

18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer

1 reference

12 December 2020

Positron emission tomography in breast cancer: a clinicopathological correlation of results

1 reference

12 December 2020

Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management

1 reference

12 December 2020

Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures.

1 reference

12 December 2020

Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose

1 reference

12 December 2020

Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry

1 reference

12 December 2020

Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience

1 reference

12 December 2020

Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma.

1 reference

12 December 2020

Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma

1 reference

12 December 2020

Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations

1 reference

12 December 2020

Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography

1 reference

12 December 2020

Association between [ 18 F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation

1 reference

12 December 2020

Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.

1 reference

12 December 2020

Diagnostic value of positron emission tomography for detecting breast cancer

1 reference

12 December 2020

Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions

1 reference

12 December 2020

Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer

1 reference

12 December 2020

Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine.

1 reference

12 December 2020

Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients.

1 reference

12 December 2020

Cancer statistics, 2001

1 reference

12 December 2020

10.1007/S11912-996-0011-Y

Identifiers

DOI

1 reference

9 August 2017

1 reference